Advanced NSCLC – Immunotherapies for Today and Tomorrow
- Discuss the evidence with current and emerging therapies for non-driver mutation advanced NSCLC
- Identify patient and disease factors impacting optimal first-line treatment approaches in advanced NSCLC.
- Discuss how these factors may guide treatment decisions for patients with advanced NSCLC in Canadian practice
- Timezone: America/New_York
- Date: Thursday, December 09, 2021
- Time: 3:00 pm - 4:00 pm
About the Faculty
Quincy Chu, MD FRCPC
I have been a medical oncologist at the Cross Cancer Institute since April 2005 with medical oncology training in Canada and subsequent phase I/clinical research fellowship in novel anti-cancer drugs at the Institute for Drug Development in San Antonio, Texas. During which I was involved in a large number of novel anti-cancer agents, and had extra training in novel trial design and clinical pharmacology. Currently, I am an Associate Professor in the Department of Oncology of University of Alberta. I continue my clinical and translational research in novel drug development, including targeted agents and immune-oncology agents, in thoracic oncology. I am the co-Lead and Lead for Phase I unit and the Thoracic Research Unit, respectively, at the Cross Cancer Institute.
David Gandara, MD
Bio to come
Barbara Melosky, MD FRCPC
Dr. Melosky is a Clinical Professor of medicine at the University of British Columbia and a medical oncologist in Vancouver at the British Columbia Cancer Agency. Dr. Melosky specializes in the field of thoracic malignancy. She is head of the Lung Tumor Group at BC Cancer.
She sits on the Executive Lung Site Committee for Canadian Clinical Trials Group CTTG. Dr. Melosky chaired the Canadian Lung Cancer Conference for the last 21 years, which is attended by over 500 participants. She organizes and chairs the Lung Cancer Journal Club. She is chair and created the British Columbia Lung Cancer Biobank.
She is published extensively and is considered a national and international expert in thoracic malignancies.
This program has been made possible through unrestricted support from Sanofi Genzyme